Odyssey Therapeutics

Summary ipo Updated Apr 30, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Boston, MA
Founded 2021
Latest Stage IPO
Total Raised $1.03B
Website https://odysseytx.com/
Sector
biotech healthcare drug-discovery ai autoimmune inflammatory-disease small-molecule

Founders

Gary D. Glick Founder, President & CEO

About

Odyssey Therapeutics is a Boston-based clinical-stage biopharmaceutical company founded in 2021 by Gary D. Glick, Ph.D., a serial biotech entrepreneur whose prior companies include IFM Therapeutics, Scorpion Therapeutics, and Lycera Corporation 14. The company develops small-molecule medicines for autoimmune and inflammatory diseases, with a lead program (OD-001) targeting RIPK2 for inflammatory bowel disease and ulcerative colitis 23. On May 8, 2026, Odyssey priced an upsized IPO of 15.5 million shares at $18, raising approximately $279M in IPO proceeds, plus a concurrent $25M private placement with TPG Life Sciences Innovations, for combined gross proceeds of approximately $304M 23. Shares began trading on the Nasdaq Capital Market under the ticker “ODTX” on May 8, 2026 23. The company has raised more than $700M across prior private rounds since its 2021 launch, including a $218M Series A (December 2021) led by OrbiMed Advisors and co-led by SR One, and an oversubscribed $213M Series D (September 10, 2025) led by SR One 456.

Funding History

Date Round Amount Lead Co-investors
2026-05-08 IPO + Private Placement $304M TPG Life Sciences Innovations (private placement) 23
2025-09-10 Series D $213M SR One Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, Wedbush Healthcare Partners 56
2021-12 Series A $218M OrbiMed Advisors SR One, Foresite Capital, Woodline Partners, Logos Capital, HBM Healthcare Investments, Colt Ventures, Creacion Ventures 4

What Investors Say

No independently sourced investor quotes found.

What Founders Say

No independently sourced founder quotes found.

Sources

  1. Chemical & Engineering News, “Odyssey Therapeutics launches with $218 million,” December 2021. Accessed April 2026. https://cen.acs.org/pharmaceuticals/drug-discovery/Odyssey-Therapeutics-launches-218-million/99/web/2021/12↩

  2. Fierce Biotech, “Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline,” May 2026. Accessed April 2026. https://www.fiercebiotech.com/biotech/odyssey-voyages-nasdaq-304m-ipo-fund-autoimmune-inflammatory-pipeline↩↩↩↩

  3. Bioxconomy, “Odyssey Therapeutics upsizes IPO to raise $304m,” May 2026. Accessed April 2026. https://www.bioxconomy.com/investment/odyssey-raises-304m-in-upsized-ipo-eyes-nasdaq-debut↩↩↩↩

  4. PR Newswire, “Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines,” December 2021. Accessed April 2026. https://www.prnewswire.com/news-releases/odyssey-therapeutics-announces-218-million-series-a-financing-to-advance-next-generation-inflammation-and-oncology-medicines-301438504.html↩↩↩

  5. Odyssey Therapeutics press release, “Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases,” September 10, 2025. Accessed April 2026. https://odysseytx.com/odyssey-therapeutics-announces-oversubscribed-213-million-series-d-financing-to-advance-clinical-pipeline-for-autoimmune-diseases/↩↩

  6. Wilson Sonsini, “Firm Advises Lead Investor SR One on Odyssey Therapeutics’ $213 Million Series D,” September 2025. Accessed April 2026. https://www.wsgr.com/en/insights/firm-advises-lead-investor-sr-one-on-odyssey-therapeutics-dollar213-million-series-d.html↩↩